Jane Street’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-62,700
| Closed | -$1.35M | – | 11545 |
|
|
2025
Q4 | $1.35M | Buy |
62,700
+52,100
| +492% | +$1.01M | ﹤0.01% | 5537 |
|
|
2025
Q3 | $162K | Buy |
+10,600
| New | +$138K | ﹤0.01% | 9831 |
|
|
2025
Q1 | – | Sell |
-296,400
| Closed | -$3.12M | – | 9398 |
|
|
2024
Q4 | $3.12M | Buy |
296,400
+284,100
| +2,310% | +$3.45M | ﹤0.01% | 3378 |
|
|
2024
Q3 | $161K | Buy |
+12,300
| New | +$187K | ﹤0.01% | 8779 |
|
|
2024
Q2 | – | Sell |
-456,500
| Closed | -$7.71M | – | 9331 |
|
|
2024
Q1 | $7.71M | Buy |
+456,500
| New | +$6.8M | ﹤0.01% | 2078 |
|
|
2023
Q4 | – | Sell |
-12,500
| Closed | -$129K | – | 9162 |
|
|
2023
Q3 | $129K | Sell |
12,500
-483,200
| -97% | -$6.47M | ﹤0.01% | 7858 |
|
|
2023
Q2 | $8.17M | Buy |
+495,700
| New | +$6.44M | ﹤0.01% | 2138 |
|
|
2022
Q3 | – | Sell |
-22,600
| Closed | -$55K | – | 9666 |
|
|
2022
Q2 | $55K | Buy |
+22,600
| New | +$92.8K | ﹤0.01% | 8898 |
|
|
2022
Q1 | – | Sell |
-43,100
| Closed | -$348K | – | 10252 |
|
|
2021
Q4 | $348K | Buy |
+43,100
| New | +$394K | ﹤0.01% | 7910 |
|
|
2021
Q2 | – | Sell |
-20,700
| Closed | -$187K | – | 9751 |
|
|
2021
Q1 | $187K | Buy |
+20,700
| New | +$167K | ﹤0.01% | 8316 |
|
Other funds holding AVDL
Jane Street's AVDL Position: Q1 2026 in Review
Jane Street sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 500,561 shares — an estimated $10.8M sold.
Jane Street first reported a position in AVDL in Q2 2014 and held it in 20 quarters. The position peaked at $10.8M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Jane Street reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 500,561 Avadel Pharmaceuticals shares in Q1 2026, an estimated $10.8M.
- Jane Street first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 20 quarters.
- Jane Street's Avadel Pharmaceuticals position peaked at $10.8M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.